Catechol-O-Methyltransferase (COMT) Gene (Val158Met) and Brain-Derived Neurotropic Factor (BDNF) (Val66Met) Genes Polymorphism in Schizophrenia: A Case-Control Study

Ramin Saravani¹,²*, Hamid Reza Galavi¹,², Marzieh Lotfian Sargazi²

Abstract

Objective: Several studies have shown that some polymorphisms of genes encoding catechol-O-methyltransferase (COMT), the key enzyme in degrading dopamine, and norepinephrine and the human brain-derived neurotropic factor (BDNF), a nerve growth factor, are strong candidates for risk of schizophrenia (SCZ). In the present study, we aimed at examining the effects of COMT Val158Met (G>A) and BDNF Val66Met (G>A) polymorphisms on SCZ risk in a sample of Iranian population.

Method: This case-control study included 92 SCZ patients and 92 healthy controls (HCs). Genotyping of both variants (COMT Val158Met (G>A) and BDNF Val66Met (G>A)) were conducted using Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR).

Results: The findings revealed that the COMT Val158Met (G>A) polymorphism was not associated with the risk/protective of SCZ in all models (OR=0.630, 95%CI=0.299-1.326, P=0.224, GA vs. GG, OR=1.416, 95%CI=0.719-2.793, P=0.314, AA vs. GG, OR=1.00, 95%CI=0.56-1.79, P=1.00 GA+AA vs. GG, OR=1.667, 95%CI=0.885-3.125, P=0.11, AA vs. GG+GA, OR=1.247, 95%CI=0.825-1.885, P=0.343, A vs. G). However, BDNF Val66Met (G>A) variant increased the risk of SCZ (OR = 2.008 95%CI = 1.008 - 4.00, P = 0.047, GA vs. GG, OR = 3.876 95%CI = 1.001 - 14.925, P = 0.049, AA vs. GG, OR = 2.272. 95%CI = 1.204 - 4.347, P = 0.011, GA+AA vs. GG, OR = 2.22 95%CI = 1.29 - 3.82. P = 0.005, A vs. G).

Conclusion: The results did not support an association between COMT Val158Met (G>A) variant and risk/protective of SCZ. Moreover, it was found that BDNF Val66Met (G>A) polymorphism may increase the risk of SCZ development. Further studies and different ethnicities are recommended to confirm the findings.

Key words: BDNF, COMT, Schizophrenia, Single Nucleotide Polymorphism

Schizophrenia (SCZ) is a complex psychiatric disorder that affects nearly 1% of the general population worldwide characterized by hallucinations, delusions, and incompatibility of mental activity and environment; however, the exact mechanisms underlying the development and progression of SCZ are still entirely unknown, but genetic factor accounts for more than 80% of etiology and heritability of SCZ (1-3). The human Catechol-O-methyltransferase (COMT) gene is located on the long arm of Chromosome 22 at Position 11.21 (22q11) microdeletion, COMT with transferring a methyl group to catecholamine due to their degrading including dopamine, adrenaline, and noradrenaline (4, 5).

The COMT polymorphism has been examined as a possible contributing role in some of psychiatric and behavioral problems; also, many studies have been conducted on the association of COMT gene as a candidate gene for SCZ, so the activity of this enzyme is regulated by a common polymorphism causing substantial variations in the activity of this enzyme (4, 6, 7).

---

1. Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
2. Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

*Corresponding Author:
Address: Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Tel: +98-543329892, Fax: +98-543329892, E-mail: saravaniramin@yahoo.com

Article Information:
Received Date: 2017/01/02, Revised Date: 2017/06/06, Accepted Date: 2017/07/10
A functional single nucleotide polymorphism (SNP) with code rs4680G>A causes guanine change to adenine (exchange between nucleotide) in the gene sequence, which produces methionine amino acid from valine amino acid (Val>Met) at Codon 158. This change, which is due to the reduction of the activity of COMT enzyme with Met vs. Val (one-fourth of the enzymatic activity), results in a slower degradation of dopamine and greater availability (8). In addition, Chen et al. reported the homozygote “Met” G 3 to 4 fold lower enzymatic activity compared with the homozygote “Val”, while the heterozygote has approximately intermediate activity (9, 10). Moreover, a previous study showed that Val allele of this SNP was associated with cognitive characterization of SCZ patients such as poor performance in tests of working memory (11). Moreover, this SNP was associated in some ethnics, while the same association did not exist in other populations (12, 13). The human brain-derived neurotropic factor (BDNF) gene, located on the short arm of chromosome 11 at Position 14.1 (11p14.1), is one member of the neurotropic factor family that promotes the development, survival, regeneration, and maintenance of the function of neurons. Several roles have been demonstrated for BDNF on the importance of BDNF such as modulate neurotransmitter, synthesis, metabolism, long-term potentiation, and postsynaptic ion channel fluxes (14). Several studies have found a change in the level of BDNF in hippocampus and the cortical area of SCZ patients; moreover, they reported that BDNF plays an important role in neurotransmission. Abundant genetic studies have shown the possible correlation between BDNF gene polymorphisms and SCZ even though some studies have not found any correlation between BDNF Val66Met polymorphism and psychiatric disorder. Furthermore, it has been demonstrated that Val66Met polymorphism of BDNF affects human memory and hippocampal function (14-17). Therefore, considering the possible importance of these 2 proteins in SCZ susceptibility and their relationship with SCZ, which have not been evaluated in any sample of Iranian population to date, in the present study we aimed at finding a relationship between COMT Val158Met (G>A) rs4680 and BDNF Val66Met (G>A) rs6265 polymorphisms and SCZ in a sample of Iranian population (Southeast of Iran).

Materials and Methods

This case-control study was performed on 92 patients with SCZ who referred to Baharan hospital in the city of Zahedan, Iran from June 2015 to June 2016). Their conditions except for the many) observed under UV disorders with major depression, schizophrenia, and bipolar disorder were selected. The case group was age and gender matched with the healthy controls (HCs) for a routine annual checkup from Ali-asghar hospital (Zahedan, Iran).

Ethics

The local ethics committee of Zahedan University of Medical Sciences (ethical code: 7716) approved the study protocol. Informed consent was obtained from all participants (and the next of kin) before participating in this study.

Genomic DNA Extraction

Genomic DNA was extracted from whole blood (2mL in EDTA-containing tubes) of the patient and control groups immediately after collection using salting-out method as described previously (20). The electrophoresis, NanoDrop, and a spectrophotometer (WPA, UK) (based on a ratio of 260/280) were used to examine the quality and quantity of the extracted DNA. The DNA samples were stored at -20°C until analysis.

PCR Reaction

The analysis of COMT Val158Met (G>A) and BDNF Val66Met (G>A) polymorphisms were performed by Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR). The list of primers, designed by using Wasp primer software, (Fisgham Company, Tehran, Iran) used for amplification of SNPs is provided in Table 1. The final PCR mixture volume was 20μL consisting of 2 μL of genomic DNA (~80-100 ng), 1.5 μL of each primer (10-pmol/μL), 10μL master mix (Ampliqon Taq 2x mastermix, Denmark), and 5 μL of DNaase-free water (SinaClon BioScience Co., Tehran, Iran). Eppendorf thermal cycler (Eppendorf AG, Hamburg, Germany) was used for amplification with the following condition: COMT Val158Met (G>A): an initial denaturation at 94 °C for 5 minutes followed by 30 cycles at 94 °C for 30 seconds; annealing 49°C for 30 seconds; extension at 72 °C for 30 seconds and at the end of the 30th cycle; the final extension was at 72 °C for 5 minutes. The BDNF Val66Met (G>A) condition was similar to the above conditions except for the annealing temperature, which was 62.°C

Gel Electrophoresis

PCR products were verified on 1.5% of agarose (Invitrogen Life Technologies, Gaithersburg, MD, USA) containing ethidium bromide (0.7μg/ml) (Sigma-Aldrich, Steinheim, Germany) observed under UV light. The sizes of PCR products were reported to be 244bp for COMT Val158Met (G>A) and 258bp for BDNF Val66Met (G>A). At least, 20% of samples, either SCZ or HCs, were regenotyped randomly, and the new results confirmed the past results.

Statistical Analysis

Statistical analyses were performed using SPSS statistical software Version 22 (SPSS, Chicago, IL, USA). The rates of the genotypes and alleles were compared using the binary logistic regression and Mann-Whitney test. Categorical data were compared using Pearson’s $X^2$ test. A probability of $p<0.05$ was considered statistically significant.
Results
The demographic characteristics of the patients with SCZ and HCs are provided in Table 2. The mean age and gender were not significantly different between the 2 groups (P>0.05). There were no significant differences between the 2 groups in other parameters such as the level of education, place of residence, and number of family members (P>0.05).

The frequencies of alleles and genotype of COMT Val158Met (G>A) and BDNF Val66Met (G>A) polymorphisms are presented in Table 3. The frequencies of allele and genotypes of COMT Val158Met (G>A) polymorphism were not significantly different between the patients with SCZ and HCs (P>0.05). Moreover, no differences were observed between the 2 groups in dominant and recessive models of COMT Val158Met (G>A) (P>0.05). The results (Table 3) indicated that BDNF Val66Met (G>A) genotype significantly increased the risk of SCZ in the codominant model (P = 0.047, GA vs. GG and P = 0.049, AA vs. GG). Furthermore, an allele of this SNP was associated with 2.2 fold higher risk of SCZ (OR = 2.2, 95%CI = 1.29-3.82, P = 0.005). In addition, BDNF Val66Met (G>A) in the dominant (GA+AA vs. GG) model indicated an increased risk of SCZ (OR = 2.27, 95%CI = 1.20-4.34, P = 0.011).

As demonstrated in Table 4, significant associations weren’t found between these two SNPs and risk of SCZ in both genders separately, except for allele frequency of BDNF polymorphism in the female group (A vs. G, p = 0.023). The BDNF Val66Met (G>A) polymorphism conformed to the Hardy Weinberg Equilibrium (HWE) in the SCZ patients and HCs (X² = 3.27, P = 0.07 and X² = 1.74, P = 0.19, respectively), another SNP, COMT Val158Met (G>A), did not confirm HWE (case, X² = 36.32, P<0.001 and HCs, X² = 14.16, P<0.001).

Moreover, the possible association between both variants and clinical and demographic characteristics of SCZ patients in the dominant model was evaluated (Table 5); no significant association was observed between genotypes of either COMT Val158Met (G>A) or BDNF Val66Met (G>A) and clinical and demographic data (P>0.05), except for age, in BDNF Val66Met (G>A) (P = 0.002).

Discussion
The findings revealed no association between COMT Val158Met (G>A) and SCZ, while the BDNF Val66Met (G>A) variant was associated with the risk of SCZ, either genotype or allele. SCZ is a multifactorial disease with unclear and unknown etiology, but several factors are possibly involved in the SCZ incidence, prevalence, and mortality such as sex, migration status, urban status, economic status, and latitude (21). It is suggested that genetic polymorphisms in COMT Val158Met (G>A) and BDNF Val66Met (G>A) may affect the pathogenesis of SCZ. In this study, the possible association between BDNF Val66Met (G>A) and COMT Val158Met (G>A), and the risk of SCZ were investigated in a sample of Iranian population (Southeast Iran). To the best of our knowledge, no study has examined the effect of the COMT Val158Met (G>A) and BDNF Val66Met (G>A) and the risk of SCZ on the Iranian population.

Table 1. Allele-Specific Polymerase (ASP), Polymerase Chain Reaction Primers sequences

| Primer 5'-3' | Product | Method |
|--------------|---------|--------|
| COMT Val158Met (G/A) rs4680: | 244bp | ARMS |
| RW:GCATGTACACCTTGGCTTCTTTC | | |
| RM:CATGTACACCTTGCTTCTCT | | |
| F:CACCTGTGCTCACTTCTC | | |
| BDNF Val66Met (G/A) rs6265 | 258bp | ARMS |
| FW:ATTGGCTGACACTTTCGAACAAA | | |
| FM:ATTGGCTGACACTTTCGAACAG | | |
| R:ATACTGTACACGCTCAAG | | |

COMT; Catechol-O-methyl Transferase,  BDNF; the human brain-derived neurotropic factor, bp; Base Pair, ARMS; Amplification Refractory Mutation System, R; Reverse, F; Forward, W; Wild, M; Mutant

Table 2. Demographic characteristics of SCZ patients and controls

| Age (year) | SCZ (n=92) | HCs (n=92) | P-value |
|------------|------------|------------|---------|
| 43.95±11.51 | 36.16±11.23 | 0.809 |
| Sex (female/male) | 38/54 | 38/54 | 1.000 |
| Level of education (illiterate/primary) | 18/74 | 19/73 | 0.854 |
| Place of residence (urban and rural) | 59/33 | 57/35 | 0.760 |
| No. family members (mean ± SD) | 6.38±2.11 | 6.19±2.29 | 0.597 |

SCZ; Schizophrenia
HCs; Healthy controls
Table 3. Genotypic and allelic frequencies of BDNF (Val66Met) and COMT (Val158Met) polymorphisms in SCZ patients and control subjects

| Gene polymorphisms | SCZ n (%) | HCs n (%) | OR (95%CI) | P-value |
|--------------------|-----------|-----------|------------|---------|
| COMT (Val158Met) rs4680 |           |           |            |         |
| Codominant         |           |           |            |         |
| GG                 | 41(44.6%) | 41(44.6%) | Ref        |         |
| GA                 | 17(18.4%) | 27(29.4%) | 0.630(0.299-1.326) | 0.224 |
| AA                 | 34(37%)   | 24(26.1%) | 1.416(0.719-2.793)  | 0.314 |
| Allele             |           |           |            |         |
| G                  | 99(54%)   | 109(59%)  | Ref        |         |
| A                  | 85(46%)   | 75(41%)   | 1.247(0.299-5.567)  |         |
| Dominant           |           |           |            |         |
| GG                 | 41(44.6%) | 41(44.6%) | Ref        |         |
| GA+AA              | 51(55.4%) | 51(55.4%) | 1.000(0.56-1.79)    | 1.000  |
| Recessive          |           |           |            |         |
| GG+GA              | 58(63%)   | 68(73.9%) | Ref        |         |
| AA                 | 34(37%)   | 24(26.1%) | 1.667(0.885-3.125)  | 0.11   |
| Allele             |           |           |            |         |
| G                  | 99(54%)   | 109(59%)  | Ref        |         |
| A                  | 85(46%)   | 75(41%)   | 1.247(0.299-5.567)  |         |
| BDNF (Val66Met) rs6265 |           |           |            |         |
| Codominant         |           |           |            |         |
| GG                 | 55(59.8%) | 71(77.2%) | Ref        |         |
| GA                 | 28(30.4%) | 18(19.6%) | 2.008(1.008-4)      | 0.047  |
| AA                 | 9(9.8%)   | 3(3.3%)   | 3.876(1.001-14.925) |         |
| Allele             |           |           |            |         |
| G                  | 138(75%)  | 160(87%)  | Ref        |         |
| A                  | 46(25%)   | 24(13%)   | 2.22(1.29-3.82)     | 0.005  |
| Dominant           |           |           |            |         |
| GG                 | 55(59.8%) | 71(77.2%) | Ref        |         |
| GA+AA              | 37(40.2%) | 21(22.8%) | 2.272(1.204-4.347)  | 0.011  |
| Recessive          |           |           |            |         |
| GG+GA              | 83(90.2%) | 89(96.7%) | Ref        |         |
| SCZ; Schizophrenia, HCs; Healthy controls, COMT; Catechol-O-methyl Transferase, BDNF; the human brain-derived neurotropic factor, CI; = Confidence Intervals, OR; Odds Ratio

Table 4. Genotypic and allelic frequencies of BDNF (Val66Met) and COMT (Val158Met) polymorphisms in SCZ patients and control subjects in male and female as separately

| Gene polymorphisms | SCZ n (%) | HCs n (%) | OR (95%CI) | P-value |
|--------------------|-----------|-----------|------------|---------|
| COMT (Val158Met) rs4680 |           |           |            |         |
| Male               |           |           |            |         |
| GG                 | 21(38.9)  | 26(48.1)  | Ref        |         |
| GA                 | 9(16.7)   | 13(24.1)  | 0.857(0.307-2.392) | 0.768  |
| AA                 | 24(44.4)  | 15(27.8)  | 1.980(0.835-4.685)  | 0.121  |
| G                  | 51(47.2)  | 65(60.2)  | Ref.        |         |
| A                  | 57(44.4)  | 43(39.8)  | 1.689(0.984-2.898)  | 0.0758 |
| Female             |           |           |            |         |
| GG                 | 20(52.6)  | 15(39.5)  | Ref.        |         |
| GA                 | 8(21.1)   | 14(36.8)  | 0.428(0.143-1.284)  | 0.130  |
| AA                 | 10(26.3)  | 9(23.7)   | 1.200(0.391-3.686)  | 0.750  |
| G                  | 48(63.2)  | 44(57.9)  | Ref.        |         |
| A                  | 28(36.8)  | 32(42.1)  | 0.618(0.418-1.538)  | 0.618  |
| BDNF (Val66Met) rs6265 |           |           |            |         |
| Male               |           |           |            |         |
| GG                 | 33(61.1)  | 41(75.9)  | Ref.        |         |
| GA                 | 17(31.5)  | 11(20.4)  | 1.919(0.792-4.651)  | 0.149  |
| AA                 | 4(7.4)    | 2(3.7)    | 2.487(0.428-14.49)  | 0.310  |
| G                  | 83(76.9)  | 93(86.1)  | Ref.        |         |
| A                  | 25(23.1)  | 15(13.9)  | 1.867(0.922-3.780)  | 0.114  |
| Female             |           |           |            |         |
| GG                 | 22(57.9)  | 30(78.9)  | Ref.        |         |
| GA                 | 11(28.9)  | 7(18.4)   | 2.141(0.264-6.410)  | 0.173  |
| AA                 | 5(13.2)   | 1(2.7)    | 6.802(0.743-62.5)   | 0.090  |
| G                  | 55(72.4)  | 67(88.2)  | Ref.        |         |
| A                  | 21(27.6)  | 9(11.8)   | 2.842(1.204-6.706)  | 0.023  |

SCZ; Schizophrenia, HCs; Healthy controls, COMT; Catechol-O-methyl Transferase, BDNF; the human brain-derived neurotropic factor, CI; = Confidence Intervals, OR; Odds Ratio
COMT enzyme is an important degradation enzyme involved in the metabolism of catecholamine, consisting of dopamine, adrenaline, and noradrenaline. Evidence shows that polymorphism of COMT gene may influence the activity of COMT enzyme; consequently, the effectiveness of COMT enzyme decreases, and slower degradation of dopamine may be involved in SCZ development (10, 22). Another gene, BDNF, is a member of the neurotropic factor family and plays a key role in the development, regeneration of neurons, and metabolism and synthesis of neurotransmitters in the brain (16). Previous studies have shown an association between polymorphism and alternation of BDNF level in patients with SCZ (14, 23).

Similarly, several investigations have indicated an association between BDNF Val66Met (G>A) polymorphism and SCZ, confirming the results of the current study. Naoe et al. performed a meta-analysis on 8 case control studies including 2156 Caucasians with SCZ and 3007 HCs and suggested that Val66Met (G>A) polymorphism of BDNF gene was significantly associated with SCZ risk (16). Neves-Pereira et al. reported that BDNF Val66Met (G>A) variant was associated with increased risk of SCZ in Scots population, either genotype or allele (24). However, in a case-control study performed by Chen et al. on Han Chinese people, BDNF Val66Met (G>A) polymorphism was not associated with SCZ development (15). Also, Watanabe et al. did not find any correlation between BDNF Val66Met (G>A) and SCZ in a sample of Japanese population (17). Contradictory to the current results, Tochigi et al. did not find any association between BDNF Val66Met (G>A) variant and risk of SCZ susceptibility in Japanese population (25). Chen-jeé Hong et al. concluded that the carriage of GA genotype of Val66Met (G>A) polymorphism of BDNF gen was associated with SCZ in Taiwanese population (15).

Similarly, there was a relationship between BDNF Val66Met (G>A) and SCZ in several case-control and meta-analysis studies in Asia (14, 26, 27). BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Also, an association was reported between BDNF Met (A) allele polymorphism and increased aggressive behavior in SCZ patients (28).

Several studies have also shown no association between COMT Val158Met (G>A) polymorphism and SCZ, approving the findings of the present study. Daniels did not find any correlation between COMT Val158Met (G>A) and SCZ in Wales (29). Similarly, Chenet et al. (30), Karayiorgou et al. (31), and Daniels et al. (29) found no significant association between Val158Met of COMT gene polymorphism and risk of SCZ in Chinese, European, and United Kingdom (UK) populations, respectively. Also, in another investigation conducted on a sample of UK population, Norton et al. reported no significant differences in genotype or allele frequencies between SCZ and HCs for Val158Met of COMT gene polymorphism (5). However, there are contradictory results; for example, Yan Wang et al. found that SNP COMT Val158Met (G>A) was significantly associated with blunted effect in Chinese with Han origin (32). In a case-control study on North American Japanese, Ohmori et al. (1998) found a significant relationship between SCZ and COMT Val158Met (G>A) (33). Also, regarding the genotype and allele of SNP, Sarah Tosato et al. found homozygosity of COMT Met/Met patients of this variant with SCZ, who had higher aggressive behavior compared to homozygosity of Val/Val individuals (34). Ali Sazci et al. found that the Val/Met heterozygosity of COMT Val158Met (G>A) genotype significantly decreased the risk of SCZ in a Turkish population (OR = 0.641, 95%CI = 0.468-0.878, P = 0.006) compared to the Val/Val COMT Val158Met (G>A) genotype. In contrast, Met/Met genotype increased the risk of SCZ compared to the reference genotype (Met/Met vs. Val/Val, OR = 2.085, 95%CI = 1.35-3.229, P = 0.001) (35). The discrepancies between these investigations concerning both SNPs may be related to environmental and genetic differences between ethnic groups and populations.

In our population, Hardy-Weinberg disequilibrium could be due to several reasons such as the structure of population in our area (different ethnic groups), migration, small sample size, and consanguineous marriages.

The current investigation had several limitations. First, based on the published and Medline data, several COMT and BDNF polymorphisms have been identified in humans, while we investigated only 1 polymorphism from each gene. Second, we did not consider the...
differences according to specific schizophrenia subtypes. Third the small sample size.

**Conclusion**
In conclusion, our results revealed a significant association between BDNF Val66Met (G>A) polymorphism and SCZ risk, not supporting an association between COMT Val158Met (G>A) and risk of SCZ in the population of Southeast Iran. Further studies with larger sample sizes and different ethnicities should be conducted to determine their effects on SCZ risk.

**Acknowledgment**
This work was supported by Zahedan University of Medical Sciences, Zahedan, Iran.

**Conflict of Interest**
The authors declare no conflicts of interest.

**References**
1. Atakhorrami M, Rahimi-Allabadi S, Jamshidi J, Moslemi E, Movafagh A, Ohadi M, et al. A genetic variant in CAMKK2 gene is possibly associated with increased risk of bipolar disorder. J Neural Transm (Vienna) 2016; 123: 323-328.
2. Ghasemvand F, Omidinia E, Salehi Z, Rahmanzadeh S. Relationship between polymorphisms in the proline dehydrogenase gene and schizophrenia risk. Genet Mol Res 2015; 14: 11681-11691.
3. Omidinia E, Mazar FM, Shahamati P, Kianmehr A, Mohammadi HS. Polymorphism of the CLDN5 gene and Schizophrenia in an Iranian Population. Iran J Public Health 2014; 43: 79-83.
4. Shifman S, Bronstein M, Sternfeld M, Pisanté S, Bronstein M, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
5. Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, et al. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am J Med Genet 2002; 114: 491-496.
6. Wonodi I, Stine OC, Mitchell BD, Buchanan RW, Thaker GK. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 120B: 47-50.
7. Zammit S, Jones G, Jones SJ, Norton N, Sanders RD, Milham C, et al. Polymorphisms in the MAOA, MAOB, and COMT genes and aggressive behavior in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128B: 19-20.
8. González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE, López-Narváez ML, Tovilla-Zárate CA, Fresan A. The Role of a Catechol-O-Methyltransferase (COMT) Val158Met Genetic Polymorphism in Schizophrenia: A Systematic Review and Updated Meta-analysis on 32,816 Subjects. Neuromolecular Med 2016; 18: 216-231.
9. Huang E, Zai CC, Lisoway A, Maciukiewicz M, Felsky D, Tiwari AK, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. Int J Neuropsychopharmacol 2016; 19: pyv132.
10. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807-821.
11. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917-6922.
12. Herken H, Erdal ME. Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatr Genet 2001; 11: 105-109.
13. Strous RD, Bark N, Woerner M, Lachman HM. Lack of association of functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 1997; 41: 493-495.
14. Numata S, Ueno S-i, Iga J-i, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2006; 401: 1-5.
15. Hong O-J, Yu YW-Y, Lin C-H, Tsai S-J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003; 349: 206-208.
16. Naoe Y, Shinkai T, Hori H, Fukunaka Y, Utsunomiya K, Sakata S, et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case–control study and meta-analysis. Neurosci Lett 2007; 415: 108-112.
17. Watanabe Y, Muratake T, Kaneko N, Nunokawa A, Someya T. No association between the brain-derived neurotrophic factor gene and schizophrenia in a Japanese population. Schizophr Res 2006; 84; 29-35.
18. Galavi HR, Saravani R, Esmaeilzaei E, Mohamadi A. Interleukin-6 receptor rs2229238/C/T and rs4845625T/C polymorphisms increase the risk of schizophrenia in an Iranian population: A pilot study. Clinical and Experimental Neuropsychology 2017; 8; 54-59.
19. Saravani R, Esmaeilzaei E, Noorzehi N, Galavi HR, Melatonin Receptor 1B Gene
**COMT and BDNF Polymorphisms and T2D**

Polymorphisms, Haplotypes and Susceptibility to Schizophrenia. Revista Română de Medicină de Laborator 2017; 25.

20. Mousavi M, Saravani R, Modrek MJ, Shahrakipour M, Sekandarpour S. [Detection of Toxoplasma gondii in Diabetic Patients Using the Nested PCR Assay via RE and B1 Genes (Persian)]. Jundishapur J Microbiol 2016; 9: e29493.

21. McGrath J, Saha S, Chant D, Welham J. Detection of Toxoplasma gondii in Diabetic Patients Using the Nested PCR Assay via RE and B1 Genes (Persian). Jundishapur J Microbiol 2016; 9: e29493.

22. Mousavi M, Saravani R, Modrek MJ, Shahrakipour M, Sekandarpour S. [Detection of Toxoplasma gondii in Diabetic Patients Using the Nested PCR Assay via RE and B1 Genes (Persian)]. Jundishapur J Microbiol 2016; 9: e29493.

23. Tochigi M, Otowa T, Suga M, Rogers M, Minato T, Yamasue H, et al. No evidence for an association between the BDNF Val66Met polymorphism and schizophrenia or personality traits. Schizophr Res 2006; 87: 45-47.

24. Kunugi H, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S. Brain-derived neurotrophic factor gene and schizophrenia: polymorphism screening and association analysis. Schizophr Res 2003; 62: 281-283.

25. Tan YL, Zhou DF, Cao LY, Zou YZ, Wu GY, Zhang XY. Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophr Res 2005; 77: 355-356.

26. Spalletta G, Morris D, Angelucci F, Rubino I, Spoletoni I, Bria P, et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010; 25: 311-313.

27. Chen C-H, Lee Y-R, Chung M-Y, Wei F-C, Koong F-J, Shaw C-K, et al. Systematic mutation analysis of the catechol O-methyltransferase gene as a candidate gene for schizophrenia. Am J Psychiatry 1999; 156: 1273-1275.

28. Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE, et al. Identification of sequence variants and analysis of the role of the catechol-O-methyl-